Mercury Content,
Ovalbulmin
μg Hg/0.5 mL Content, μg/0.5 mL
Age Indications
Route
IMc
0
≤1.0
≥9 yb
24.5
≤1.0
≥9 y
0
≤0.05
3y
IMc
0
—d
≥18 y
IMc
<25.0
≤0.3
≥3 y
IMc
≤1.0
≤1.0
≥4 y
IMc
25.0
≤1.0
≥4 y
0
—e
6–35 mo
IMc
0
—e
≥36 mo
IMc
0
—e
≥36 mo
IMc
25.0
—e
≥6 mo
IMc
0
—
18–64 y
Intradermalg
0
—e
≥65 y
IMc
0
≤0.05
≥3 y
IMc
<25.0
≤0.3
≥3 y
IMc
0
—e
6–35 mo
IMc
0
—e
≥36 mo
IMc
0
—e
≥36 mo
IMc
0
0
18–49 y
IMc
0
(per 0.2 mL)
<0.24
(per 0.2 mL)
2–49 yj
Intranasal
e
b
f
Inactivated influenza vaccine, intradermal: a 0.1-mL dose contains 9 μg of each vaccine antigen
(27 μg total).
The preferred site is over the deltoid muscle. Fluzone Intradermal is administered using the delivery
system included with the vaccine.
h
Inactivated influenza vaccine, high-dose: a 0.5-mL dose contains 60 μg of each vaccine antigen
(180 μg total).
i
See PI for Warnings and Precautions: http://www.medimmune.com/docs/default-source/defaultdocument-library/product-and-patient-information-for-flumist-quadrivalent.pdf ?sfvrsn=0.
j
FluMist is indicated for healthy, nonpregnant persons ages 2–49 years. Caregivers of severely
immunosuppressed persons who require a protective environment should not receive FluMist.
g
7
